Advertisement
Singapore markets closed

  • Straits Times Index

    3,290.70
    +24.75 (+0.76%)
     

  • Nikkei

    38,229.11
    +155.13 (+0.41%)
     

  • Hang Seng

    18,963.68
    +425.87 (+2.30%)
     

  • FTSE 100

    8,433.76
    +52.41 (+0.63%)
     

  • Bitcoin USD

    60,809.74
    -2,386.65 (-3.78%)
     

  • CMC Crypto 200

    1,257.34
    -100.67 (-7.41%)
     

  • S&P 500

    5,222.68
    +8.60 (+0.16%)
     

  • Dow

    39,512.84
    +125.08 (+0.32%)
     

  • Nasdaq

    16,340.87
    -5.40 (-0.03%)
     

  • Gold

    2,366.90
    +26.60 (+1.14%)
     

  • Crude Oil

    78.20
    -1.06 (-1.34%)
     

  • 10-Yr Bond

    4.5040
    +0.0550 (+1.24%)
     

  • FTSE Bursa Malaysia

    1,600.67
    -0.55 (-0.03%)
     

  • Jakarta Composite Index

    7,088.79
    -34.81 (-0.49%)
     

  • PSE Index

    6,511.93
    -30.53 (-0.47%)
     

New Strong Sell Stocks for August 27th

Zacks Equity Research
·1-min read

Here are five stocks added to the Zacks Rank #5 (Strong Sell) List today:

Cardlytics, Inc. CDLX operates an advertising platform within financial institutions digital channels. The Zacks Consensus Estimate for its current year earnings has been revised 57.9% downward over the last 30 days.

Energy Fuels Inc. UUUU engages in the extraction, recovery, exploration, and sale of conventional and in situ uranium recovery. The Zacks Consensus Estimate for its current year earnings has been revised 23.5% downward over the last 30 days.

Invacare Corporation IVC designs, manufactures, distributes, and exports medical equipment for use in home health care, retail, and extended care markets. The Zacks Consensus Estimate for its current year earnings has been revised 11.5% downward over the last 30 days.

ADVERTISEMENT

Poseida Therapeutics, Inc. PSTX is a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The Zacks Consensus Estimate for its current year earnings has been revised 9.8% downward over the last 30 days.

Cytokinetics, Incorporated CYTK is a late-stage biopharmaceutical company. The Zacks Consensus Estimate for its current year earnings has been revised 15.7% downward over the last 30 days.

View the entire Zacks Rank #5 List.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Poseida Therapeutics, Inc. (PSTX) : Free Stock Analysis Report
 
Cytokinetics, Incorporated (CYTK) : Free Stock Analysis Report
 
Energy Fuels Inc (UUUU) : Free Stock Analysis Report
 
Invacare Corporation (IVC) : Free Stock Analysis Report
 
Cardlytics, Inc. (CDLX) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research